A game-changing collaboration to accelerate drug development for Alzheimer's disease

The Critical Path Institute's (C-Path) Critical Path for Alzheimer's Disease (CPAD) Consortium today announced its participation as a Partner with the Alzheimer's Disease Data Initiative (ADDI), a 501(c)(3) medical research organization which launched today.

ADDI is dedicated to advancing scientific breakthroughs in the treatment of Alzheimer's disease (AD) and related dementias.

ADDI will be a game-changing collaboration to provide the necessary data accessibility to advance data-driven solutions to accelerate Alzheimer's disease drug development. C-Path is honored to be a key Partner with ADDI, through CPAD, and contribute our data science, model-informed drug development and regulatory science expertise to ensure the success of ADDI."

Klaus Romero, M.D, M.S, F.C.P, Chief Science Officer, Critical Path Institute (C-Path)

CPAD's integrated and standardized patient-level database comprised of randomized clinical trials from industry, which is currently available to qualified researchers across the globe, will be a relevant and crucial component of ADDI's Alzheimer's Disease Workbench.

This will enable researchers in AD and related dementias around the world to interact with relevant data resources more efficiently and accelerate the generation of actionable scientific insights leading to innovative solutions, diagnostic tools and therapies in AD.

Emphasizing the expected impact of ADDI, CPAD's Executive Director Sudhir Sivakumaran, Ph.D., said, "ADDI is uniquely positioned to maximize the value of each data point contributed by individuals living with AD, who participate in clinical trials, observational studies, patient registries and other research efforts."

CPAD's Industry Co-Director and Vice President, Clinical Research, Neurology Business Group, Eisai, Inc. Michael C. Irizarry, M.D., M.P.H, added, "In this important initiative, the CPAD partnership with ADDI aims to facilitate increased aggregation and robust analysis of high-quality AD clinical research data, to model disease progression and help accelerate the development of biomarkers and therapeutics."